Compare AbbVie Inc (ABBV) vs FMC Corp (FMC) Price & Performance

AbbVie IncTrade

FMC CorpTrade

Price performance (Past 24H)

Key statistics

AbbVie Inc vs FMC Corp — how do they compare? AbbVie Inc trades at $249.72 (market cap $441.94B), while FMC Corp trades at $10.13 (market cap $1.30B). The key difference: AbbVie Inc is far larger — about 340× FMC Corp's market cap, and FMC Corp pays the higher dividend (3.07%). Which is the better fit depends on your goals.

	ABBV	FMC
Market Cap	$441.94B	$1.30B
Sector	Health	Basic Materials
52-Week High	$263.58	$40.69
52-Week Low	$197.38	$10.01
Enterprise Value	$506.19B	$5.11B
Dividend Yield	2.77%	3.07%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbbVie Inc

AbbVie (ABBV) trades at $247.91, up 0.76% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 70.73% buy consensus highlight robust fundamentals, driven by Skyrizi and Rinvoq growth offsetting Humira declines. Positive news includes Phase 2 ovarian cancer data and institutional stake increases, reinforcing momentum.

Outlook remains positive with a $278.69 price target, though risks include patent cliffs and debt levels. Revenue growth and dividend stability offer appeal, but investors should monitor competitive pressures and regulatory developments for sustained performance.

FMC Corp

FMC stock trades at $10.46, down 1.23% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $2.24 billion in 2025, with negative profitability margins, though recent quarters show mixed earnings beats. Analyst consensus is divided, with a $11.60 price target, while recent news highlights revenue challenges and strategic moves like a $400 million investment from Tessenderlo Group to reduce debt.

The outlook remains cautious due to persistent losses and weak revenue trends, but debt reduction efforts and cost controls offer some stability. Key risks include competitive pressures and macroeconomic headwinds, while the current valuation metrics like P/S of 0.4 may attract value investors if operational improvements materialize.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

ABBV

Fidelity Dividend ETF's payout is safe but not ideal for steady income due to variable quarterly dividends.24/7 Wall Street · 1 day agoNeutral Two Dividend Aristocrats outperformed the market while two lagged; three new picks show promising dividend growth.24/7 Wall Street · 2 days agoNeutral Healthcare sector leads S&P 500 gains over 3 months with key pharma stocks showing strong innovation and income potential.24/7 Wall Street · 2 days agoBullish View details →

FMC

View details →

About AbbVie Inc

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

About FMC Corp

FMC is a pure-play crop chemical company. The company has diversified its sales to create a balanced crop chemical portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop chemical companies and will continue to develop new products, with a focus on biologicals, through its research and development pipeline.